Decision-IQ: Managing Off Episodes in Parkinson’s Disease With Available and Emerging Therapies
Robert Hauser, MD, MBA
Professor of Neurology
Director, USF Health Byrd Parkinson’s Disease and Movement Disorders Center
University of South Florida
Julie Blum, PhD
Senior Clinical Content Manager
Lisa R. Rinehart, MS, ELS
Director, Editorial Services
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Upon completion, participants should be able to:
- Evaluate the benefits and limitations of available management strategies to reduce off time and treat off episodes in patients with PD
- Summarize the efficacy, safety, and mechanisms of action for investigational and emerging therapies for the treatment of off episodes in PD
This activity is intended for neurologists.
Statement of Need
Management strategies for off episodes in Parkinson’s disease (PD) are currently limited. Although current strategies can help reduce off time resulting from the wearing off of levodopa, they do not benefit those who experience unpredictable off times, delayed on times, or no on episodes. Only one therapy is currently approved by the Food and Drug Administration (FDA) to treat off episodes, but others are currently in development. Neurologists would benefit from becoming familiar with the mechanisms of action, safety, and efficacy of current and emerging therapies for the treatment of off episodes so that the better understand the benefits and limitations of these strategies to appropriately advise their patients with PD on their use.Providership Statement
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: June 29, 2018
Expiration Date: June 28, 2019
Estimated Time to Complete This Activity: 15 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Robert Hauser, MD, MBA
Consulting fees/advisory boards: AbbVie Inc., ACADIA Pharmaceuticals Inc., Acorda Therapeutics, Adamas Pharmaceuticals, Inc., AstraZeneca, Back Bay Life Science Advisors, Biotie Therapies, Bracket, Cerecor, Inc., ClearView Healthcare Partners, ClinicalMind, Cowen Inc., Cynapsus Therapeutics, DR/Decision Resource, LLC, Eli Lilly and Company, ERT Clinical, ExpertConnect, Extera Partners, GE Healthcare, Gerson Lehrman Group, Inc., Globe Life Sciences, Guidepoint Global, LLC, Health Advances LLC, Health and Wellness Partners, LLC, HealthLOGIX, Huron Consulting Group Inc., Impax Laboratories, LLC, IntecPharma, Jazz Pharmaceuticals, Kyowa Kirin Pharmaceutical Development, Inc., LCN Consulting, LifeMax, Lundbeck, MEDACorp, Inc., Medtronic, Inc., Neurocrine Biosciences, NeuroDerm, Neuropore Therapies, Inc., Pennside Partners Ltd, Pfizer, Inc., PharmaTwoB, Piper Jaffray Companies, Prexon Therapeutics, Putnam Associates, Quintiles, Sarepta Therapeutics, Schlesinger Associates, Scion NeuroStim LLC, Seagrove Partners, Slingshot Insights, Sunovion Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Lockwood Group, US WorldMeds, LLC, Vista Research Group, LLC, Windrose Counsulting Group
The peer reviewers and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email email@example.com.
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Google Chrome - latest version
Apple Safari - latest version
Adobe Acrobat Reader® or Adobe Reader
Adobe Flash Player
Adobe Flash Player 9 or later
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc.
© 2018 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.